SUTRO BIOPHARMA, INC. Quarterly Income Tax Expense (Benefit) in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Sutro Biopharma, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2022 to Q3 2024.
  • Sutro Biopharma, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000, a 100% decline year-over-year.
  • Sutro Biopharma, Inc. annual Income Tax Expense (Benefit) for 2023 was $18.2M, a 628% increase from 2022.
  • Sutro Biopharma, Inc. annual Income Tax Expense (Benefit) for 2022 was $2.5M.
  • Sutro Biopharma, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000, a 100% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $0 -$1.84M -100% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $8K -$143K -94.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q4 2023 $18.2M $15.8M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 $1.84M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $151K -$2.35M -94% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $395K +$395K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q2 2022 $2.5M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.